You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

NIVL+IPIL

Cancer Type: Genitourinary, Renal cell / Kidney      Intent: Palliative
Regimen Category: Evidence-informed
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma

You might also be interested in